We really can't promise both more transplants and better outcomes. The controversies over organ allocation really represent intellectual exhaustion in the face of a long series of inadequate policy responses to the decade-long trend of the kidney supply increasing only at the expense of organ quality and patient outcomes.
When a would-be living organ donor wants to accept risk in the name of altruism when there is little chance for benefit or significant chance for harm, physicians are justified in limiting that altruism.
This month, Virtual Mentor's theme issue editor for March 2012, Alon Neidich, interviewed Dr. Al Roth about the growing importance of paired kidney exchanges for incompatible patient-donor pairs.
When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
Though there are channels through which terminally ill patients can access some experimental drugs that have not yet received FDA approval for marketing to the public, in general those drugs must already be proven safe and effective.
When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
Jessie Kimbrough-Sugick, MD, MPH, Jessica Holzer, MA, and Eric B. Bass, MD, MPH
Researchers who approach community partners with an agenda already in hand are missing the point of the community-based participatory research enterprise: developing priorities for study together.
By privileging traditional research methods in forms for research protocol approval, IRBs can unknowingly allow community partners to be harmed in CBPR. Changes to the language can help ensure appropriate sensitivity and community involvement.